Mineralys Therapeutics, Inc. 8-K

What Happened

• Mineralys Therapeutics, Inc. (MLYS) announced its financial results for the quarter ended March 31, 2026 and provided a corporate update via a press release issued May 6, 2026. The company furnished the release as Item 2.02 (Results of Operations and Financial Condition) in a Current Report on Form 8-K.

Key Details

• Press release dated May 6, 2026 covers Mineralys’ quarterly results for the period ended March 31, 2026 and includes a corporate update.
• The press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference in the filing.
• The filing notes, per Form 8-K General Instruction B.2, that the information (including Exhibit 99.1) is furnished and should not be deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• This 8-K furnishes Mineralys’ latest quarterly results and operational update—key information investors use to assess recent revenue, earnings trends, cash position and near-term prospects.
• Because the press release is furnished (not “filed”) under Section 18, it has different legal treatment; investors should read the full Exhibit 99.1 press release and await any subsequent SEC filings (e.g., quarterly report) for additional audited or detailed financial disclosures.